Effects of Henagliflozin Proline and Metformin XR on Body Composition in Geriatric Patients With Newly Diagnosed T2DM

A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 116 participants.

Also called NCT07323381

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 116 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07323381
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07323381. Randomized; no masking; primary purpose treatment. Start 2025-12-30 (anticipated); primary completion 2027-09-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Effects of Henagliflozin Proline and Metformin XR on Body Composition in Geriatric Patients With Newly Diagnosed T2DM
Acronym
HABIT-GEMs
Condition
Diabetes Type 2
Intervention (Drug)
Henagliflozin Proline Tablets treatment
Intervention (Drug)
Metformin XR treatment
Lead sponsor
Bin Lu (class: other)
Collaborator
Shanxi Provincial People's Hospital (class: other government)
Collaborator
Zhongnan Hospital (class: other)
Collaborator
Second Affiliated Hospital of Soochow University (class: other)
Collaborator
The Second Affiliated Hospital of Shandong First Medical University (class: other)
Collaborator
Fifth Affiliated Hospital, Sun Yat-Sen University (class: other)

Record details

Record id
cardio:ct-nct07323381
Content hash
c5e63c11bfb3efeb151014cb193881bfb9de8904d952572154fbc111019e682b